To assess the effect of miglitol versus repaglinide on postprandial hyperglycemia and glycosylated hemoglobin in Type-2 diabetes mellitus. METHODOLOGY: This open-labeled randomized glycaemic control. parallel group prospective clinical trial of 16-week duration included 60 patients of Type-2 diabetes randomly assigned to receive miglitol 25 mg thrice a day for four weeks followed by 50 mg thrice a day for 12 weeks or repaglinide 0.5 mg thrice a day for four weeks followed by 1 mg thrice a day for 12 weeks. Glycosylated hemoglobin, fasting and postprandial plasma glucose levels were assessed at the start and end of the study. RESULTS: The mean glycosylated hemoglobin, postprandial plasma glucose levels as well as fasting plasma glucose decreased significantly in miglitol as well as repaglinide group (P<0.001). There was no significant difference in the reduction of glycosylated hemoglobin between miglitol (1.14%) versus repaglinide group (1.45%, P=0.32). The postprandial glucose reduction in miglitol group (88.5 mg%) was not different from repaglinide (101.2 mg%, P=0.23). Similarly reduction in fasting glucose between miglitol (45.6 mg%) and repaglinide (40.86 mg%) was not significantly different (P=0.73). Conclusion: Miglitol and repaglinide are equally efficacious in reducing postprandial glucose levels, fasting glucose levels as well as glycosylated hemoglobin.